Aflibercept 8mg Intravitreal Injection
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of aflibercept 8mg intravitreal injection.
Aflibercept 2mg (biosimilar when available) remains a first line treatment option (alongside ranibizumab biosimilar).
Aflibercept 8mg can be used in those patients that have not responded sufficiently to the 2mg treat and extend protocols and that aflibercept 8mg will be used no more frequently than every 8 weeks in line with the licence
NICE TA346 was published in July 2015 and the PCN recommends Aflibercept as a treatment option in the treatment of Diabetic Macular Oedema. A treatment pathway will be developed in consultation with local ophthalmologists and will be brought to a future PCN for consideration
